. Effects of neurokinin receptor antagonists in virus-infected airways. Am J Physiol Lung Cell Mol Physiol 279: L59-L65, 2000.-We investigated the effects of a neurokinin-1 (NK 1 ) receptor antagonist (SR-140333) and a NK 2 receptor antagonist (SR-48968) on airway responsiveness and on the function of neuronal M 2 muscarinic receptors, which normally inhibit vagal acetylcholine release, in guinea pigs infected with parainfluenza virus. Antagonists were given 1 h before infection and daily thereafter. Four days later, bronchoconstriction induced by either intravenous histamine (which is partly vagally mediated) or electrical stimulation of the vagus nerves was increased by viral infection compared with control. In addition, the ability of the muscarinic agonist pilocarpine to inhibit vagally induced bronchoconstriction was lost in virus-infected animals, demonstrating loss of neuronal M 2 receptor function. Macrophage influx into the lungs was inhibited by pretreatment with both antagonists. However, only the NK 1 receptor antagonist prevented M 2 receptor dysfunction and inhibited hyperresponsiveness (measured as an increase in either vagally induced or histamine-induced bronchoconstriction). Thus virus-induced M 2 receptor dysfunction and hyperresponsiveness are prevented by a NK 1 receptor antagonist, but not by a NK 2 receptor antagonist, whereas both antagonists had similar anti-inflammatory effects.
M 2 muscarinic receptors on the vagus nerves in the lung, which normally inhibit acetylcholine release (20) , are no longer functional in virus-infected guinea pigs (18) .
Multiple mechanisms are involved in virus-induced loss of neuronal M 2 muscarinic receptor function. Dysfunction of inhibitory M 2 muscarinic receptors may be a direct effect of the virus itself. Viral neuraminidase cleaves sialic acid residues from the M 2 receptors, thereby decreasing agonist affinity for the receptors (17) . Furthermore, parainfluenza virus decreases gene expression for the M 2 receptors (26) . Alternatively, inflammatory cells and their products may be important participants in loss of M 2 receptor function in airway disease. Cyclophosphamide pretreatment of guinea pigs before viral infection depletes leukocytes, and in these animals, M 2 receptor function is preserved except in animals with very severe infections in which the direct effects of the virus on M 2 receptor function are seen (22) .
In antigen-challenged guinea pigs, eosinophils are responsible for M 2 receptor dysfunction (11, 16) . Binding of eosinophil major basic protein to the M 2 receptors blocks the negative feedback normally provided by binding of acetylcholine to the receptors (19, 24) . We have shown that blockade of the neurokinin-1 (NK 1 ) receptors prevents loss of M 2 receptor function in antigen-challenged guinea pigs. However, the influx of eosinophils into the airways is not blocked by NK 1 receptor antagonists. Because tachykinins can activate eosinophils and cause release of eosinophil granule proteins (30) , it seems likely that the NK 1 receptor antagonist prevents antigen-induced M 2 receptor dysfunction by preventing eosinophil activation.
Eosinophils are not involved in virus-induced loss of M 2 receptor function because depletion of eosinophils or of eosinophil major basic protein did not protect M 2 function or prevent hyperresponsiveness (1) . However, the effects of tachykinins in the airways are potentiated by viral infections. Virus-induced loss of neutral endopeptidase activity decreases the breakdown of tachykinins (25) , potentiating their effects on airway smooth muscle (10) and increasing neurogenic inflammation (34) . Because tachykinins may be involved in the activation of neutrophils and macrophages (4, 32) and these cells are increased with viral infection, we investigated the role of tachykinins in airway hyperresponsiveness and M 2 receptor dysfunction after viral infection.
METHODS
Virus stock and titration. Parainfluenza type 1 (Sendai virus, ATCC) was grown in rhesus monkey kidney cell monolayers in L-15 medium for 1 wk at 34°C. Cultures were frozen and thawed to disrupt cells, and the fluids were cleared by low-speed centrifugation and stored in aliquots at Ϫ70°C.
Viral content was determined by exposing fresh rhesus monkey kidney cell monolayers to serial 10-fold dilutions of the stock solution. After 1 wk of incubation at 34°C, the monolayers were washed and the medium was replaced with a 0.5% suspension of guinea pig erythrocytes. After 1 h, the erythrocytes were washed off and the monolayers were examined under an inverted phase-contrast microscope (Olympus) for evidence of hemadsorption [sticking of erythrocytes to the surface of cells expressing the viral hemagglutinin on their surfaces (38) ]. Viral content was determined as the multiple of the amount of stock solution required to produce infection in 50% of rhesus monkey kidney monolayers [the 50% tissue culture infection dose (TCID 50 )].
Virus infection. Dunkin-Hartley guinea pigs (female, 250-350 g, specific pathogen free; Hilltop Animal Farms; Scottsdale, PA) were anesthetized with ketamine (45 mg/kg im) and xylazine (8 mg/kg im). Animals in the infected group were inoculated intranasally with 1 ml of virus solution that contained 10 5 TCID 50 /ml obtained by diluting the viral stock in Dulbecco's phosphate-buffered saline. Animals in the uninfected (control) group were inoculated intranasally with fluids obtained from virus-free rhesus monkey kidney cells that were prepared and diluted in phosphate-buffered saline in the same way as the viral solutions. Control and infected animals were housed in separate laminar flow hoods.
Virus isolation and titration. After physiological studies were completed, the guinea pig lungs were removed and stored at Ϫ70°C. Frozen samples were thawed, weighed, and homogenized in 2 ml of phosphate-buffered saline (Polytron, Brinkman; Lucerne, Switzerland). Virus was eluted from the tissue homogenate by incubation at 34°C for 1 h. The suspensions were centrifuged at 400 g for 30 min, and the viral content of the supernatants was determined by inoculating rhesus monkey kidney cell monolayers as above.
Treatment with neurokinin receptor antagonists. Guinea pigs were treated with either a NK 1 receptor antagonist [SR-140333, 1 mg/kg sc (2)] or a NK 2 receptor antagonist [SR-48968, 0.2 mg/kg sc (12) ]. In three guinea pigs, the effect of a higher dose of the NK 2 antagonist (1 mg/kg) was also tested. Antagonists were given 1 h before infection and daily thereafter for a total of four doses. The final dose of antagonist was given 24 h before physiological studies were done. To exclude the possibility that the effects of the NK 1 antagonist on M 2 receptor function were the result of residual NK 1 antagonist, we treated two virus-infected guinea pigs with the NK 1 receptor antagonist (1 mg/kg iv) at the time of the physiological experiments and tested the effects on M 2 receptor function as described below.
Anesthesia and measurement of pulmonary inflation pressure. Four days after inoculation with virus or with control medium, guinea pigs were anesthetized with urethan (1.5 g/kg) injected intraperitoneally. This dose of urethan produces a deep anesthesia lasting 8-10 h. None of the experiments described lasted longer than 3 h, and the depth of anesthesia was monitored by observing for fluctuations in heart rate and blood pressure. Guinea pigs were handled in accordance with the standards established by the Animal Welfare Acts set forth in National Institutes of Health guidelines and the Policy and Procedures Manual published by the Johns Hopkins University School of Hygiene and Public Health Animal Care and Use Committee.
Once the guinea pigs were anesthetized, a carotid artery was cannulated for measurement of blood pressure and heart rate. Cannulas were placed into both jugular veins for the administration of drugs. Both vagi were cut, and the distal portions were placed on shielded platinum electrodes immersed in a pool of liquid paraffin. The body temperature of the animal was maintained at 37°C using a heating blanket.
The animals were paralyzed with succinylcholine (infused at 10 g ⅐ kg Ϫ1 ⅐ min
Ϫ1
), tracheostomized, and ventilated using a positive-pressure, constant-volume animal ventilator (Harvard Apparatus; South Natick, MA; tidal volume 2.5-3.5 ml, 100 breaths/min). Pulmonary inflation pressure (P pi ) was measured with a Spectromed pressure transducer (DTX). All signals were displayed on a Grass polygraph.
A positive pressure of 85-100 mmH 2 O was needed for adequate ventilation of the animals. Given constant flow and volume, bronchoconstriction was measured as the increase in P pi over the baseline inflation pressure (9) . The P pi signal from the driver was fed into the input of the preamplifier of a second channel on the polygraph, and the baseline P pi was subtracted electrically. Thus P pi was recorded on one channel and increases in P pi were recorded on a separate channel at a higher sensitivity. With this method, it was possible to accurately measure increases in P pi as small as 2 mmH 2 O above baseline.
Airway response to vagal stimulation. All animals were pretreated with guanethidine (10 mg/kg iv) to deplete norepinephrine. The vagus nerves were cut bilaterally, and the distal portions were placed on pairs of platinum electrodes. The vagi were stimulated bilaterally (1-25 Hz, 0.2-ms pulse duration, 10 V, 44 pulses per train), and the increase in P pi was recorded.
M 2 receptor function. Airway neuronal M 2 muscarinic receptor function was assessed as the ability of the muscarinic agonist pilocarpine to inhibit the airway response to vagal stimulation. The nerves were stimulated regularly at 1-min intervals (2 Hz, 0.2-ms pulse duration, 4-10 V, 44 pulses per train). Once a stable baseline response to vagal stimulation had been established, pilocarpine (0.1-100 g/kg) was administered intravenously and the effect on vagally induced bronchoconstriction was determined. Doses of pilocarpine greater than 30 g/kg produced a transient bronchoconstriction. Therefore, the effect of these doses of pilocarpine on vagally induced bronchoconstriction was measured after the P pi had returned to baseline. Doses of pilocarpine greater than 100 g/kg were not used because they caused sustained bronchoconstriction via stimulation of muscarinic receptors on the airway smooth muscle. At the end of each experiment, vagally induced bronchoconstriction and bradycardia were abolished by atropine (1 mg/kg iv), indicating that both of these responses were mediated via release of acetylcholine onto muscarinic receptors.
Responsiveness to histamine. Histamine (1-20 nmol/kg) was injected intravenously, and the increase in P pi was recorded. Histamine responsiveness was measured in animals before and after vagotomy. In the absence of vagotomy, the second histamine dose-response curve was superimposable on the first, as we have described previously (8) .
Measurement of inflammatory cells. At the end of each experiment, after the physiological measurements were completed, the lungs were lavaged five times with 10-ml aliquots of warm phosphate-buffered saline. Lavage fluids were centrifuged (400 g, 10 min) and the pellets were resuspended in normal saline. Cell counts were done using a hemocytometer. Slides made of lavaged cells using a cytospin were stained with Diff-Quik (American Scientific Products) and used to determine cell differentials.
Drugs. Pilocarpine, succinylcholine, atropine, histamine, guanethidine, urethan, and L-15 medium were purchased from Sigma (St. Louis, MO). Ketamine was purchased from Aveco (Fort Dodge, IA). Xylazine was purchased from Mobay (Shawnee, KS). SR-140333 and SR-48968 were generous gifts from Dr. X. Emonds-Alt (Sanofi Recherche; Montpellier, France). All drugs were dissolved and diluted in 0.9% NaCl. Rhesus monkey kidney cells were purchased from Viromed (Minnetonka, MN).
Statistics. Results are expressed as the means Ϯ SE. The effects of viral infection and of pretreatment with neurokinin receptor antagonists on dose-response curves to pilocarpine were compared using two-way analysis of variance (ANOVA) for repeated measures. Similar analysis was used to determine the effects of viral infection, vagotomy, and pretreatment with neurokinin receptor antagonists on histamineinduced bronchoconstriction as well as the effects of viral infection and neurokinin receptor antagonists on vagally induced bronchoconstriction. Viral content of the lungs and cell counts and differentials in various groups of animals were compared using one-way ANOVA. P Ͻ 0.05 was considered significant.
RESULTS

Viral infection.
All animals exposed to parainfluenza virus became infected as shown by recovery of infectious virus from lung homogenates into rhesus monkey kidney cells. Viral content of lungs from non-neurokinin antagonist-treated animals was 3.9 ϫ 10 6 Ϯ 2.4 ϫ 10 6 TCID 50 /g lung tissue (n ϭ 13), whereas that from NK 1 antagonist-treated animals was 4.8 ϫ 10 6 Ϯ 2.7 ϫ 10 6 TCID 50 /g lung tissue (n ϭ 13) and that from NK 2 antagonist-treated animals was 4.4 ϫ 10 6 Ϯ 3.3 ϫ 10 6 TCID 50 /g lung tissue (n ϭ 7). There were no significant differences among the viral titers in the three groups, and no virus was recovered from control (uninfected) animals.
Physiological measurements and M 2 receptor function. Baseline P pi was increased by viral infection [87 Ϯ 5.7 mmH 2 O in control and 155 Ϯ 5.9 mmH 2 O in infected animals (P Ͻ 0.0001)]. This virus-induced increase was attenuated but not abolished by pretreatment with either the NK 1 antagonist (115 Ϯ 9.5 mmH 2 O; P ϭ 0.0013 vs. virus alone, P ϭ 0.036 vs. control) or the NK 2 antagonist (126 Ϯ 7.4 mmH 2 O; P ϭ 0.0084 vs. virus alone, P ϭ 0.002 vs. control). Baseline heart rate was not affected by any of the treatments.
Electrical stimulation of the vagus nerves caused bronchoconstriction (measured as an increase in P pi ) and bradycardia. Both responses were frequency dependent. Vagally induced bronchoconstriction was potentiated in virus-infected guinea pigs (Figs. 1 and  2 ). This hyperresponsiveness to vagal stimulation was prevented by pretreatment with the NK 1 receptor antagonist ( Fig. 1) but not by the NK 2 receptor antagonist (Fig. 2) . In uninfected animals, vagally induced bronchoconstriction was inhibited by pilocarpine in a dose-dependent fashion, demonstrating M 2 receptor function. This response was lost in virus-infected animals (Figs. 3 and  4) , demonstrating loss of M 2 receptor function. M 2 receptor dysfunction was prevented by pretreatment with the NK 1 receptor antagonist (Fig. 3) but not by the NK 2 receptor antagonist (Fig. 4) . A higher dose of the NK 2 receptor antagonist (1 mg/kg) also failed to prevent virus-induced M 2 receptor dysfunction (data not shown). In virus-infected animals not previously treated with the NK 1 antagonist, acute administration of the NK 1 antagonist (1 mg/kg iv) at the time of the physiological experiments did not restore M 2 receptor function (data not shown).
Intravenous injection of histamine caused dosedependent bronchoconstriction. Histamine-induced bronchoconstriction was potentiated in virus-infected guinea pigs (Fig. 5) . This hyperresponsiveness to histamine was largely, but not completely, reversed by vagotomy. Likewise, pretreatment with the NK 1 receptor antagonist largely, but not completely, prevented virus-induced hyperresponsiveness to histamine (Fig. 5) . In virus-infected animals that had been pretreated with the NK 1 antagonist, vagotomy returned the responsiveness to histamine to control levels (Fig. 5) .
Leukocytes in lung lavage fluid. In lung lavage fluid, total leukocyte counts were increased by viral infection, and this increase was prevented by treatment with either the NK 1 or the NK 2 antagonist (Fig. 6) . The increase in total cells was made up primarily of neutrophils. A small but significant attenuation of the neutrophil influx was seen after pretreatment with the NK 2 antagonist. Macrophages were not increased significantly by viral infection. However, macrophages were decreased in virus-infected animals by pretreatment with either the NK 1 or the NK 2 antagonist, although the effect of the NK 2 antagonist did not achieve statistical significance (P ϭ 0.06). Thus the effects of the antagonists on total cell numbers are the result of combined effects on neutrophils and macrophages. . This is largely reversed by vagotomy (n ϭ 12), which also decreases the response to histamine in uninfected controls (n ϭ 17). In virus-infected animals that were pretreated with the NK 1 receptor antagonist (NK 1 A) SR-140333, hyperresponsiveness was prevented (n ϭ 10). A small further decrease in responsiveness was seen in virus-infected animals that were pretreated with the NK 1 receptor antagonist SR-140333 and vagotomized (n ϭ 8; means Ϯ SE).
DISCUSSION
These data show that viral infection causes airway hyperresponsiveness and dysfunction of inhibitory M 2 muscarinic receptors via mechanisms that are largely dependent on stimulation of the NK 1 receptors. In control guinea pigs, the muscarinic agonist pilocarpine inhibited vagally induced bronchoconstriction in a dose-dependent manner, confirming that neuronal M 2 muscarinic receptors were functioning to inhibit release of acetylcholine (20) . In contrast, viral infection caused loss of M 2 muscarinic receptor function because pilocarpine no longer inhibited vagally induced bronchoconstriction (Figs. 3 and 4) . Viral infection also induced hyperresponsiveness to both histamine and vagal nerve stimulation compared with noninfected controls (Figs. 1, 2, and 5) .
In virus-infected animals that were treated with the NK 1 receptor antagonist, M 2 receptor function was preserved (Fig. 3) . This prevented hyperresponsiveness to vagal stimulation (Fig. 1) and largely attenuated the hyperresponsiveness to histamine (Fig. 5) . Treatment with the NK 2 antagonist did not prevent either M 2 receptor dysfunction (Fig. 4) or the resulting vagal hyperresponsiveness (Fig. 2) .
Blocking the NK 1 receptors resulted in significant suppression of the inflammatory response to viral infections, primarily by inhibiting the influx of macrophages (Fig. 6) . However, blocking the NK 2 receptor had a similar effect (Fig. 6 ) but did not prevent M 2 receptor dysfunction or the airway hyperresponsiveness. Thus preventing the influx of inflammatory cells into the airways does not appear to be the mechanism for the effects of the NK 1 receptor on the M 2 receptor and on vagal responsiveness.
The lack of concordance between the effect on the inflammatory response and the effect on M 2 receptor function is similar to our previous description of the effects of neurokinin receptor antagonists on antigeninduced hyperresponsiveness and M 2 receptor dysfunction (7) . In this case, neither NK 1 antagonists nor NK 2 antagonists blocked antigen-induced airway inflammation (which consisted largely of eosinophils). However, NK 1 antagonists (but not NK 2 antagonists) prevented M 2 receptor dysfunction and airway hyperresponsiveness. We subsequently demonstrated the importance of NK 1 receptors stimulating release of major basic protein from eosinophils, causing M 2 receptor dysfunction and airway hyperresponsiveness (14) .
Although tachykinins have important direct effects on cholinergic neurotransmission, these are not likely to be responsible for the current findings. Physiological studies were done at least 24 h after the last dose of neurokinin receptor antagonist when no antagonist would be expected to remain. Furthermore, we have shown that the NK 1 antagonist, given at the time of the physiological studies, did not acutely reverse the M 2 receptor dysfunction (data not shown).
We have previously demonstrated multiple mechanisms by which viral infections can cause M 2 receptor dysfunction and airway hyperresponsiveness (22) . Depleting inflammatory cells by pretreating with cyclophosphamide prevents M 2 receptor dysfunction in the majority of virus-infected guinea pigs. In some animals, however, M 2 receptor function is lost despite the prevention of lung inflammation by cyclophosphamide. The viral content of the lungs is substantially higher in guinea pigs that lose M 2 receptor function despite cyclophosphamide treatment than in those in which the M 2 receptor function is preserved. This suggests the possibility that in animals with severe viral infections, there may be a direct effect of the virus on M 2 receptor function.
We have suggested two mechanisms by which the virus may directly affect M 2 receptor function. Parainfluenza virus-induced pulmonary M 2 receptor dysfunction may be the result of cleavage of sialic acid residues from M 2 receptors by viral neuraminidase, which decreases agonist affinity for the receptors by an order of magnitude (17) . Alternatively, virus-induced airway M 2 receptor dysfunction may be a direct effect of viral infection on M 2 receptor gene expression in the airway nerves. Using primary cultures of airway parasympathetic nerves, we have shown that viral infection of these cells decreases M 2 receptor gene expression by Fig. 6 . Pretreatment with either a NK 1 or a NK 2 receptor antagonist attenuates the inflammatory response to viral infection. Viral infection (n ϭ 11) caused a substantial increase in total leukocytes in the bronchoalveolar lavage fluid; this increase was composed primarily of neutrophils. In virus-infected animals that had been pretreated with either the NK 1 receptor antagonist SR-140333 (n ϭ 5) or the NK 2 receptor antagonist SR-48968 (n ϭ 5), the increase in total cells was blocked. Macrophages were not increased significantly by viral infection. However, macrophages were decreased in virus-infected animals by pretreatment with either the NK 1 or the NK 2 antagonist, although the effect of the NK 2 antagonist did not achieve statistical significance (P ϭ 0.06; means Ϯ SE). A small but significant attenuation of the neutrophil influx was seen after pretreatment with the NK 2 antagonist. * P Ͻ 0.05 compared with virus alone. two orders of magnitude (26) . This loss of M 2 receptor gene expression is accompanied by increased release of acetylcholine and by functional evidence of loss of inhibitory M 2 receptor effect.
Loss of M 2 receptor function may also be the result of airway inflammation, as is the case after inhalation of antigen or ozone (11, 16, 23) . In both ozone-(40) and antigen-exposed (15, 19) guinea pigs, release of eosinophil major basic protein, which is an M 2 receptor antagonist (24) , is responsible for loss of M 2 receptor function.
In contrast, eosinophils are not responsible for virusinduced M 2 receptor dysfunction and hyperresponsiveness. Depleting eosinophils using antibody to interleukin-5 does not prevent these effects of viral infections, and virus-induced M 2 receptor dysfunction cannot be reversed by neutralizing major basic protein (22) .
Although the precise inflammatory cells responsible for virus-induced M 2 receptor dysfunction have not yet been identified, we have demonstrated that interferon-␥, which is produced in response to viral infections, may be involved. Treating primary cultures of airway parasympathetic neurons with interferon-␥ (300 U/ml) for 24 h caused substantial loss of M 2 receptor function and increased acetylcholine release. This was accompanied by a marked decrease in M 2 receptor gene expression (26) .
Tachykinins, signaling via the NK 1 receptor, may be involved in production of interferon-␥. Substance P has been shown to stimulate production of interferon-␥ by clones of T helper cells (31) and to potentiate the stimulated release of interferon-␥ by peripheral blood mononuclear cells (33) . Furthermore, treatment of mice with the NK 1 receptor antagonist Spantide II decreases interferon-␥ production in mice infected with Salmonella (29) , whereas the production of interferon-␥ is markedly decreased in NK 1 receptor knockout mice infected with Schistosoma mansoni (5) .
We have demonstrated the role of M 2 receptor dysfunction in increasing vagally mediated bronchoconstriction in several models of airway disease (18, 21, 36) . Furthermore, in antigen-challenged guinea pigs, the increased vagal acetylcholine release that results from M 2 receptor dysfunction is responsible for the increased response to histamine (8) . Thus it is the reflex component of the response to histamine that is potentiated.
Studies in humans with naturally occurring viral infections likewise suggest that reflex bronchoconstriction is potentiated. Empey et al. (13) demonstrated that the response to inhaled histamine was increased in subjects with viral infections. The response to histamine was returned to the level of controls if subjects were treated with atropine, demonstrating that it was the vagal reflex component of the response that was increased. Similar effects were found by Aquilina et al. (3) using cold air as the stimulus.
Hyperresponsiveness to histamine in virus-infected guinea pigs is also largely vagally mediated. Buckner et al. (6) demonstrated that atropine reverses hyperresponsiveness to histamine in parainfluenza virus-infected guinea pigs. In the current studies, we showed that the vagally mediated component of the response to histamine is increased by M 2 receptor dysfunction in virus-infected animals. Vagotomy substantially decreases the hyperresponsiveness to histamine. However, it does not abolish it, suggesting that another, vagally independent mechanism exists in addition. Likewise, pretreatment with the NK 1 receptor antagonist largely, but not completely, blocked the increase in responsiveness to histamine. In these animals, subsequent vagotomy eliminated the residual histamine hyperresponsiveness.
One possibility to explain the vagus-independent hyperresponsiveness to histamine was proposed by Sekizawa et al. (37) . In these studies, parainfluenza infection of guinea pigs decreased the activity of the histamine-degrading enzyme histamine N-methyltransferase and in this way increased the effects of histamine on the airway smooth muscle. The role of stimulation of NK 1 receptors in mediating this effect of viral infections has not been investigated.
In conclusion, viral infection causes M 2 muscarinic receptor dysfunction, leading to increased vagal acetylcholine release. Both effects appear to require stimulation of NK 1 receptors and are blocked by a NK 1 receptor antagonist but not by a NK 2 receptor antagonist. The hyperresponsiveness to histamine is also largely mediated through increased vagal reflex resulting from M 2 receptor dysfunction. This is again attenuated by the NK 1 receptor antagonist. The NK 1 receptor antagonist suppresses the inflammatory response to viral infections, but in this respect it does not appear to be substantially different from the NK 2 receptor antagonist. This suggests that the effects of the NK 1 receptor antagonist are not the result of an interruption of the recruitment of inflammatory cells, although they may be the result of interference with inflammatory cell activation.
